VIVE - Viveve Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0500
+0.0100 (+0.96%)
As of 1:16PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.0400
Open1.0500
Bid1.04 x 1100
Ask1.05 x 1000
Day's Range1.0400 - 1.0700
52 Week Range0.9300 - 4.5500
Volume28,928
Avg. Volume281,186
Market Cap47.1M
Beta (3Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-1.73
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.38
Trade prices are not sourced from all markets
  • Zacks Small Cap Researchlast month

    VIVE: Q4 Preannouncement, 2019 Guidance / Strategic Restructuring

    Earlier this week Viveve (VIVE) preannounced expected Q4 revenue of ~$4.4M (~16% ahead of our since-revised estimate), issued initial 2019 revenue guidance of $20.0M (~17% below our since-revised estimate) and outlined an already-underway operational restructuring plan aimed at slashing expenses and refocusing sales efforts at the physician (i.e. Q4 numbers (vs our estimates) are 57 (vs 55 E) unit sales, including 48 (vs 40 E) in the U.S. and 9 (vs 15) OUS and 4,600 (vs 5,047 E) consumable treatment tips. The ~$4.4M in expected Q4 revenue implies declines of 13% from Q4’17 and 8% from Q3’18.

  • GlobeNewswirelast month

    Viveve Reports Preliminary Full Year 2018 Financial Results, Announces 2019 Revenue Guidance and Provides Corporate Update

    Viveve Medical Inc. (VIVE), a medical technology company focused on women's intimate health, today reported preliminary financial results for the full year ended December 31, 2018 and provided revenue guidance for 2019. The company also announced it has implemented changes to the Viveve organization to reduce operating expenses and focus on label expansion and market development for its cryogen-cooled monopolar radiofrequency (CMRF) technology.

  • GlobeNewswire2 months ago

    Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

    “As we seek to achieve regulatory clearances for our CMRF technology for the treatment of SUI, a condition that affects an estimated 25-30 million women worldwide, completion of enrollment in the LIBERATE-International trial is an important milestone,” stated Scott Durbin, chief executive officer and director of Viveve. “Our single-session procedure offers women the potential for significant improvement in urine leakage and the ability to engage in their daily lives with greater comfort and control. LIBERATE-International is a multicenter, randomized, double-blinded, and sham-controlled trial with an enrollment of approximately 100 subjects at up to ten study sites in Canada.

  • Zacks Small Cap Research2 months ago

    VIVE: 12-Month SUI Feasibility Study Data Further Supports Compelling Efficacy Signal

    It has been a busy few weeks for Viveve (VIVE). In addition to raising nearly $19M (net) via the sale of common shares, they recently announced compelling 12-month results from their n=36 SUI feasibility study and got the green light from FDA to forge ahead with VIVEVE II (their pivotal U.S. study in sexual function). Earlier this month Viveve announced 12-month results of its feasibility study evaluating their Viveve System technology for the treatment of women with mild-to-moderate stress urinary incontinence (SUI).

  • GlobeNewswire2 months ago

    Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to continue enrollment in the company’s multicenter randomized Viveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical trial to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function in women following vaginal childbirth. The Agency determined that the company provided sufficient data to support continued subject enrollment in the trial and that there are no safety concerns that preclude the continuation of the study.

  • GlobeNewswire2 months ago

    Viveve Announces Closing of Public Offering of Shares of Common Stock

    Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The net proceeds to Viveve from the offering were approximately $18.8 million, after deducting underwriting discounts and commissions (but before deducting estimated offering expenses payable by the Company). Viveve intends to use the net proceeds from this offering to support the continued commercialization of its products in North America and internationally, to obtain additional regulatory clearances and to conduct the VIVEVE II Sexual Function and LIBERATE – International and LIBERATE – U.S. stress urinary incontinence (SUI) clinical trials, and for general corporate and working capital purposes.

  • GlobeNewswire3 months ago

    Viveve Announces Pricing of Public Offering of Shares of Common Stock

    Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The gross proceeds to Viveve from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Viveve, are expected to be $20.0 million. All shares of common stock are being offered by Viveve.

  • GlobeNewswire3 months ago

    Viveve Announces Proposed Public Offering of Shares of Common Stock

    Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock will be offered by Viveve. Viveve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock in connection with the public offering.

  • GlobeNewswire3 months ago

    Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders

    The live webcast of this event can be accessible through the company’s investor relations website at http://ir.viveve.com. Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. In the second quarter of 2018, Viveve initiated VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth following an Investigational Device Exemption (IDE) application approval from the U.S. Food and Drug Administration (FDA) in March of 2018.

  • Zacks Small Cap Research3 months ago

    VIVE: Short-Term Headwinds Result in Lowered Guidance. Clinical Progress Sets Up Several Upcoming Milestones

    Viveve (VIVE) reported Q3 2018 financial results and provided a business update. While VIVE was not one of the seven, we are not overly surprised that this has caused what appears to be an overly cautious market reaction given FDA’s language in the letter that these devices (i.e.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of VIVE earnings conference call or presentation 9-Nov-18 1:00pm GMT

    Q3 2018 Viveve Medical Inc Earnings Call

  • 9 Colorado companies make Deloitte’s list of fastest-growing tech companies
    American City Business Journals3 months ago

    9 Colorado companies make Deloitte’s list of fastest-growing tech companies

    Of the nine Colorado companies on the list, five are software companies and two are in biotech or pharmaceuticals.

  • Simply Wall St.4 months ago

    Does The Viveve Medical Inc (NASDAQ:VIVE) Share Price Tend To Follow The Market?

    If you’re interested in Viveve Medical Inc (NASDAQ:VIVE), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of VIVE earnings conference call or presentation 9-Aug-18 9:00pm GMT

    Q2 2018 Viveve Medical Inc Earnings Call

  • Zacks Small Cap Research6 months ago

    VIVE: Sales Force Realignment Appears To Be Paying Dividends As Q2 U.S. Systems Sales Crush Prior Record

    Viveve (VIVE) reported Q2 2018 financial results and provided a business update. While international sales faltered, falling 18% from the prior year, that overseas weakness was much more than offset by extraordinarily robust domestic sales. Strength of the U.S. business, which also saw big gains on treatment tip ASPs and resultant widening of related margins, was attributed to increased production following the sales force realignment.